# Harmony Biosciences Presents Pipeline Strategy at Piper Sandler CNS Symposium, Shares BP-205 Phase 1 Data

> clinical trial · REPORTED · 2026-08-13

At the Piper Sandler Virtual CNS Symposium on August 13, 2026, Harmony management outlined a life-beyond-WAKIX strategy centered on pitolisant franchise extensions, the orexin-2 agonist BP-205, and rare-epilepsy candidate EPX-100. The company had reported record Q2 2026 WAKIX net revenue of $261.3 million (up 30% year-over-year) and initial Phase 1 SAD data for BP-205 showing favorable PK and safety profiles on August 4, 2026.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a Plymouth Meeting, PA-based pharmaceutical company that develops and commercializes therapies for patients with rare neurological diseases, led by its narcolepsy drug WAKIX (pitolisant).

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.investing.com/news/transcripts/harmony-biosciences-at-piper-sandler-virtual-cns-symposium-pipeline-push-93CH-4859517

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.